everyone, an share thank with today. call. exciting Good you I today's morning, a been and to lot you time has company. It joining for have for our
believe on driven we that diabetes shareholders.
On X to continuous focus are monitor be planning Our company will looking and our I value has growth been which meaningful long-term to or growth, one, today, elements: our our want now year, over significantly future for we management. for past create and will transformed key the glucose by call CGM the to the drivers
in are projected year over is As rapidly. the excited to a vast about our towards billion pioneering launch we solution, a incredibly and commercial $XX that already of opportunity we worth innovative approach this next-generation and market, presents our progress market grow
in our addition, and order technology, strategic with investment to a innovative through more building value preeclampsia shareholders of out opportunities potential pipeline of provide products asepsis for technology. are diagnostic cancer plus acquisition In high-growth prostate test accretion, we in the
existing X. strong our you plan, profitability also and update infrastructure listing by support speak to from execution is on we as I our strengthening as of deficiencies future This business I of establishing NASDAQ increasing continued which R&D comprehensive three, how business well many growth our our successfully will an on And Moving for addressing for to transformation important existing removing the company the and balance sheet strengthened would lines. finally, stock. value overhang of would lines. have the our
let I areas, address each speak first Before X me performance. of QX our to those
grow same press are growth by base, the our at reducing to you while a TrinScreen we cost. saw continuing time revenues. in As today's year-on-year revenue driven HIV saw We release, revenue X%
ordering a market. revenues Our is are the in this as compared but QX, quarter-on-quarter, a to TrinScreen lower which HIV rapid of result different of feature QX were patterns only test
TrinScreen for HIV year And million. $XX approximately are in guidance of press sales we this today's HIV. release, XXXX of QX TrinScreen our for in set revenues of higher revenue as expect We out reiterating
QX due during customers compared to XXXX, Our mainly revenues normal lower high patterns QX 'XX certain testing from revenues XXXX. were to rate, ordering hemoglobin AXc even XXXX to products QX unusually an from than due having the primarily run
impairment loss from enhancing improvement. our a $X.X execution initiatives restructuring the Continued in million XXXX, a million in to and disciplined charges before QX decrease on contributed XX% to $X.X profitability operating
early the our profitability to end were and and executing not of completed or spent transformation be have as profitability. them adding in significantly our on the to scheduled I initiatives to in speak will year most this yet such, As XXXX, later, comprehensive at planning many we plan, of while very are this year
are our very due line am as in confirm XXXX. plan, many that such, change Louise in step the we on this are year or early on financial profitability you of However, to to cusp a the our And be in happy bring that more we will I with end results expect call. near-term performance. the detail executed through of by later QX our
leadership driving you the solution and team. growth walk our of from areas long-term lab-based diagnostic X more tests. our our acquired across through Beginning me provide some recently details let for main and with key priority achievements CGM Now new innovative
mentioned, the as for design this presents about changing. are the incredibly next-generation are vast this our this of progress rapidly I in With CGM diabetes to excited breakthrough we for innovative solution market the growing game company are respect and solution. opportunities we in management, making The
and Having entirely the developing components. that need globally, per broad cost products markets. around do their a of the know mainly consulted is with built not of given range a established day both disposable and This current clinical in satisfactorily solutions are commercial or reducing stakeholders that is a need we address main critical products CGM
specifically market solution are need. designing our We next-generation to this address
solution you, sensor our nonreusable proprietary glucose next-generation remind of amount capitalizes technology components. down the on To to our reduce
patch, applicator approach sensor paired This low-cost great a As simplified and designed result, cost our breakthrough disposable and modular per give both a both with new transmitter reduces design, all to day experience. waste. reusable significantly user a a
and to proposition to and our our captured to beyond solution. the believe and similar new Our the points key these of solution data further design data points wearable value devices. watches will glucose, strengthen of capture smart many also physiological We points by other additional differentiate insights data users, allows provide
to glucose than have say of and solution. achievable glucose companies get much an functions accurately measure this understand a trying we smart data rather accurate watch We some I could believe other as a we the suppose a developing monitor smart to many are incorporates you tried, that watch more of wearables. collection is continuous
the of our on incredible this technology. previously we sensor capitalize market to first opportunity. successfully we trial quickly as moving are pre-pivotal And updated We completed reported,
are would sensor which the feed we provide a further larger choices. will our pre-pivotal week, trial, on developments This sensor second into data technology which starting extensive on design
components are steps the supported CGM reusable great differentiated of will a this three, higher capture a value are we experience; lead and cost diabetes to a to one our allow more believe Biotech an enhance with the management position and product We We in user on; insights; a proposition. Trinity through leading and emphasis taking, reduce globe data will partners, markets. and take that two, by impressive confident
strategic are technology alike. CGM in Additionally, interest receiving inbound as for previously, have we our significant we commercial mentioned and both partners
these as assets strategic optionality for shareholder create as our value. create and build to solutions continue nurture to well We
Finally, players and we are and I'm with prepare establishing relationships premium across pleased market strategic to scaling rapid manufacturing the efficient large-scale upon for to chain launch. globe report that supply
vertical creation tests which and Now the technology an to new long-term let's the The of changes U.S. turn Administration, FDA, additional the growth new to to set LDTs. our acquisitions or value acquisitions, form Drug catalyst recent Food of lab by developed introduction lab-based strategy. for regarding these and our the recent is the rules
such in ability and U.S. the EpiCapture's certified changes We not expect recent York New tests, preeclampsia as test of FDA test to that prostate laboratory laboratories Health developed are that will Department of limit cancer the the reference market Metabolomics' new State bring these to
of which a New our Health certified, As with is York advantage, on competitive us have capitalize acquisitions. sought Department this State lab these provides with we X Immco to
FDA address route support capabilities New Trinity with to was with and provided market. products our and to laboratory us important Trinity's issues. their capital-efficient innovative established companies to those Biotech change attract and strategy new leverage to to this clinical We with and large-scale, that and rule opportunities combine technologies York attractive State and believe new acquire products technologies urgent
evaluated treatment area, our one this were these large areas; of lead new path for sophisticated three, technology and to and utilization diagnostics we As disease patients; focused opportunities criteria next-generation differentiated on; platforms. two, that important in
prostate over and the diagnosed $XXX And about in men among common their X diagnosis example, X cost annually. cancer cancer during the for For treatment men with is is billion the most lifetime. estimated at U.S. in nonskin
unnecessarily to significant complications. accurately the can monitor lead can biopsies prostate ability slow be prostate is cancer interventions as critical growing as to invasive The disease and progression often such
of market. This the curve The for technology intervention, value by new breakthrough us of Biotech, and allowing innovative using a analysis. epigenetic in test EpiCapture could offers and patients. oncology significantly and disease thereby introduce these life Trinity is The area to a improving to to frequency the thus quality EpiCapture test high-value the technology the approach disease move our progression company large-scale up reduce to monitoring
mothers which has impacts Similarly, of preeclampsia, of Metabolomics our to up other new of shown issue proprietary deliver and PrePsia death can in or and technology the risk pregnancy. Diagnostics affected week in babies. serious addresses to large the illness scale prediction Diagnostics which at X% improved The Metabolomics cause of pregnancies acquisition, preeclampsia been preterm XX U.S.
of detection of would Metabolomics powered The learning and becoming machine preeclampsia can and uses effective is issues increases spectrometry, capabilities our to technology the learning, prescription and, new serious allow bioinformatics, Trinity for in in combined with which of health diagnostics. exposure risk medication, their often babies. the care which innovative reduce particular, mothers a which again modern aspect increasingly is of critical machine for test significantly and Early health mass a to This Biotech.
enable line leverage XX.X% our our can information we strategic is Regarding capabilities rapid to physicians strategic development is and provide commercialization life-saving support treatment. Novus to have Diagnostics existing a and to groundbreaking test a time of which rationale to sepsis the made XX-minute in diagnosis This technology. Novus' that faster investment,
treatment, diagnosis limitations is lives enabling This such significantly $XX addresses diagnostics, key solution the rapid current the timely estimated Novus' cost faster in annual of sepsis over platform reducing to saving billion by improve and outcomes point-of-care sepsis-related in delay U.S. the in sepsis hospitalization and results. expected potentially as
of areas second X today. key the want the to turning on Now focus to I
we make and continue Our progress plan, significant remains comprehensive track. on to transformation on which
address these with the initiatives scale. causes existing operations on is inefficiency larger historical profitability business Our root pave of enhance transforming by our and the the of growth a for to aim to lines way value
this several objectives to accomplish. we Under plan, have
process submissions to relevant consolidation partner. milestone, and through the partner. costs with both offshore In have this a manufacturing made permit product our reduced now offshore significant manufacturing regulator manufacturing. successfully our of production completed we international of tests our rapid offshore to HIV have In regard, of the to commercial rapid we second HIV First, transfer
both begin XXXX. QX We in expect offshore of production to products
working expect We and margin be capital accretive shift meaningful gross benefits. will provide this
our We to are test of of aspects technical production to of transfer both HIV partner. of rapid our offshore some also beginning more the
next further support gross this to In our margin fact, Once partner. site change profitability a on place, weeks X with the and already team have for we enhancements. in
out at into carried City progress Kansas existing We manufacturing to to by significant We our on other plants. activities in at hemoglobin City of main continued plant end manufacturing our our of remain main currently XXXX. make our have the Kansas the consolidating activities track site cease X
staff informed our also York New recently activities Buffalo, at our plant. into have intention main manufacturing autoimmune of Jamestown, We its to consolidate York, site test our manufacturing New at
cease We XXXX. of main site expect by end the at to our manufacturing QX activities Buffalo
focused our regard, in opportunities We to test end are we've supply and continued saving chain also this identify XXXX. on the In to QX in chain. place supply our rapid have them by HIV optimizing expect further of material
efficiency offshore many of to to services agility. our drive plan we both centralize and corporate Lastly, and
our number of operating from services is site live, now with a site. As the corporate functions planned, offshore
QX the through XXXX. end profitability. We of XXXX functions expect These into changes improved and will to additional support add
every business. those focusing X offshore is sites in significant and simplification to thank that much of of manufacturing believe with completed, X are Our this or will and modernized just to enhancement. have I part X of take ambitious we aspects profitability as comprehensive and drive complex our would This activities important model. this in efficient more a is on set the With the Once less either outsourced. the U.S. Ireland, operating business journey. cooperation almost transformation efficiency our I more products, wide-ranging, aspect plan and to like main to staff, impacting expected for and support their opportunity complex manufacturing led transformation the including leave our during
and In effective our efficient and support more corporate to services centralized offshore site the business. give addition, should platform us a
plan, our once-off to our of continue today run execution annualized and items EBITDASO, share Given are approximately rate strong tax, million options or and by transformation costs $XX achieve revenues approximately charges run million impairment this. excluding range before QX to our interest, depreciation and towards continued earnings XXXX, comprehensive annualized we and rate execute of of reiterating wide will guidance $XX on we
out closing year. be to pleased difficult over extremely I'm a company past period thirdly, the and Finally, for the
CEO to I One requirement the in of the listing my top XXXX deficiencies. pre-existing priorities December NASDAQ on company's address was role when took
have important NASDAQ an with stock. We and on removed now listing our compliance regained overhang requirements
for our of process. grateful are this employees continued and the We support shareholders, partners during
satisfied So made am I overall, our on we months have priorities. with to conclude, the progress few ambitious very over past significant the
execution at the significant We possible, will preparing our our the disciplined as transformation cancer CGM, prostate while pre-cancer. in rapidly remain that in focused so with for program on as programs profitability, exciting company future transition to time, we goals, same comprehensive and
will results all more I discuss QX the Chief Louise like now you for I would hand you to to to Tallon, attention. over thank our financial Financial your And detail. Officer, in
